Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Puma Biotech (PBYI) Surges Following Results; Analyst Sees Few Excuses Not to Own
March 1, 2019 10:51 AM ESTPuma Biotech (NASDAQ: PBYI) pushes to highs following earnings after the close. Shares are up 42% on volume that is running 24x the norm.
Citi analyst Yigal Nochomovitz said with the launch back on track, they see few excuses left not to own... More
Puma Biotechnology (PBYI) PT Raised to $37 at RBC Capital
March 1, 2019 6:51 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $37.00 (from $29.00) while maintaining a Sector Perform rating following results.
MacKay called results "unexpectedly impressive" with +16% q/q growth versus a tepid +4% in Q3.
"Inventory confounds the... More
Puma Biotech (PBYI) Misses Q4 EPS by 3c
February 28, 2019 4:11 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.80), $0.03 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $71.1 million versus the consensus estimate of $53.65 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
... More